已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes

血管抑制剂 阿柏西普 医学 黄斑变性 自然科学 眼科 视力 加药 贝伐单抗 外科 内科学 化疗
作者
Faye Horner,Peck Lin Lip,Bashar Mohammed,William Fusi-Rubiano,Eesha Gokhale,Bushra Mushtaq,Randhir Chavan
出处
期刊:Clinical Ophthalmology [Dove Medical Press]
卷期号:Volume 15: 1703-1713 被引量:5
标识
DOI:10.2147/opth.s305141
摘要

To compare and report the 2-year treatment outcomes from 3 different anti-VEGF treatment regimens in treating neovascular aged-related macular degeneration (nAMD): Ranibizumab pro re nata (Ranibizumab-PRN); Ranibizumab treat and extend (Ranibizumab-T&E); Aflibercept fixed first year dosing (7 injections) with treat and extend in subsequent year (Aflibercept-Fixed).All treatment-naïve nAMD patients who completed 24 months of monitoring from a single treatment center were included. Patients received the initial loading dose of three injections (4-weekly interval), followed by one of the 3 treatment regimens. Primary outcomes were changes in visual acuity (VA) and central retinal thickness (CRT). Secondary outcome was number of injections required in each year. Data analysis included last observation carried forward (LOCF) for patients with incomplete year-2 follow-up.A total of 249 eyes (230 patients) were studied: 121 Ranibizumab-PRN; 65 Ranibizumab-T&E, and 63 Aflibercept-Fixed. Baseline median VA (ETDRS letters) for Ranibizumab-PRN, Ranibizumab-T&E, and Aflibercept-Fixed was 53.9, 61.1, and 54.9 letters, achieving final VA of 54.9, 65.1, and 65.1 letters, respectively. Hence, the number of letters increased at the end of 24 months for each group was +1.0 (Ranibizumab-PRN), +4.0 (Ranibizumab-T&E), highest +10.2 in Aflibercept-Fixed group. Median number of injections over 2 years (year-1/year-2) was 5/1 for Ranibizumab-PRN, 9/6 for Ranibizumab-T&E, and 7/5 for Aflibercept-Fixed. Both Ranibizumab-T&E and Aflibercept-Fixed also shared the same reduction of median CRT (115 µm), higher than Ranibizumab-PRN (83 µm).We report VA improvement from all three different treatment regimens with both Aflibercept-Fixed and Ranibizumab-T&E regimens achieving the same higher final VA. Aflibercept-Fixed dosing may have more favorable efficacy with the highest VA gain and comparatively lower dosing frequency whereas Ranibizumab-T&E may be more efficient than Ranibizumab-PRN regimen, according to our study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lizigongzhu发布了新的文献求助10
4秒前
小研大究完成签到,获得积分10
7秒前
陈海伦完成签到 ,获得积分10
13秒前
归海梦岚完成签到,获得积分0
13秒前
科小白完成签到 ,获得积分10
16秒前
17秒前
年轻元冬发布了新的文献求助10
18秒前
Debbieee发布了新的文献求助10
19秒前
君寻完成签到 ,获得积分10
22秒前
smile完成签到 ,获得积分10
24秒前
科研通AI2S应助小王顶呱呱采纳,获得10
25秒前
27秒前
YuanLeiZhang完成签到,获得积分10
29秒前
pathway完成签到 ,获得积分10
30秒前
木mu完成签到 ,获得积分10
32秒前
34秒前
搜集达人应助淡定海亦采纳,获得10
36秒前
年轻元冬完成签到,获得积分10
37秒前
39秒前
fanyueyue应助酷炫的冰淇淋采纳,获得10
39秒前
41秒前
孙文杰完成签到 ,获得积分10
43秒前
小学生的练习簿完成签到,获得积分0
46秒前
热心市民小红花应助morena采纳,获得10
46秒前
47秒前
淡定海亦发布了新的文献求助10
47秒前
48秒前
48秒前
黎乐荷发布了新的文献求助10
51秒前
wuhao88完成签到 ,获得积分10
51秒前
共享精神应助淡定海亦采纳,获得10
54秒前
54秒前
白云垛完成签到,获得积分10
54秒前
科目三应助wildeager采纳,获得10
55秒前
minya完成签到,获得积分10
55秒前
英俊的铭应助葛力采纳,获得10
58秒前
Ling完成签到 ,获得积分10
59秒前
59秒前
万能图书馆应助sopha采纳,获得50
1分钟前
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989949
求助须知:如何正确求助?哪些是违规求助? 3532017
关于积分的说明 11255865
捐赠科研通 3270829
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882233
科研通“疑难数据库(出版商)”最低求助积分说明 809216